FDA
-
-
-
-
-
-
-
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
-
-
-
-
-
-
-
BMO Capital Downgrades Replimune Group (REPL) to Underperform
-
-
-
-
-
-
-
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Leerink Partners Upgrades Replimune Group (REPL) to Outperform
-
-
-
-
-
-
-
Replimune Provides Update Following Type A Meeting with FDA
-
-
-
-
-
-
-
Important Notice to Long-term Shareholders of Replimune Group, Inc. (REPL): Grabar Law Office Investigates Claims on Your Behalf
-
-
-
-
-
-
-
Leerink Partners Reiterates Outperform Rating on Replimune Group (REPL), PT $21, 'Estimates Under Review'
-
325,726 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

